• Reference Citation Analysis
  • v
  • v
  • Find an Article
  • Find an Author
Find an Article (54975213)   Find a Category (126)   Find a Journal (6151)   Find a Scholar (4058)   Find an Academic Assistant (17)
Find an Article PDF (4588427)   Today's Articles (4709)   Subscriber (49277)
Download
Citation(s) in RCA

Indexed Articles
Ranked By
Results Analysis
  •   
  •   
  •   
  •   
Results Analysis
Year Published
Show more   Refine
Article Type
Show more   Refine
MESH Headings
Show more   Refine
Grant Agencies
Show more   Refine
Countries/Regions
Show more   Refine
Affiliations
Show more   Refine
For: Ou S, Solomon B, Shaw A, Gadgeel S, Besse B, Soo R, Abbattista A, Thurm H, Toffalorio F, Wiltshire R, Bearz A. 1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1616] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]  Open
Number Cited by Other Article(s)
1
Nagasaka M, Ou SHI. Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC. J Thorac Oncol 2021;16:532-536. [DOI: 10.1016/j.jtho.2020.12.021] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Accepted: 12/18/2020] [Indexed: 01/24/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA